Evidence-in-Action™ Signature Services:
Payer Readiness & Evidence Strategy for Biotech and MedTech
Turn Evidence Into Action
Evidence-in-Action™ is our portfolio of signature services for Biotech and MedTech innovators navigating the gap between clinical evidence and payer coverage decisions. We also offer an Evidence Accelerator, Investor version for Venture Funds looking to de-risk one or more life science investments within their portfolio holdings.
Four services. One connected system.
Each offering in the Evidence-in-Action™ portfolio addresses a distinct stage of evidence maturity.
Services are designed to stand alone or build on each other as your program advances.
- Evidence Snapshot™
Low-barrier introductory consultation - Evidence Accelerator™
Payer-readiness audit - Evidence Architect: RWD™
Full-lifecycle strategic advisory - Evidence Communicator™
Translate findings to deployment messages
Each service is purpose-built for a specific stage of evidence strategy.
Start where you are, then add-on.
We Help You Develop Proof for Payers
Regulatory approval and payer coverage do NOT have the same finish line.
- The FDA asks: “Is this product safe and effective?”
- Payers ask: “Is this product worth paying for compared to what we already cover?”
These are fundamentally different questions, and they can require fundamentally different evidence.
Companies that treat them as the same question often arrive at launch with regulatory approval in hand WITHOUT a practical path to reimbursement.
By the time those gaps surface, you may be facing a 12- to 24-month coverage delay.
Our Evidence-in-Action™ program series was built to systematically identify and recommend options for closing that gap, at a stage where it’s still fixable.
About MedNavigate
Learn about us, our founder and our partners.
— Dr. Nancy Hedlund, PhD, MBA
Founder, MedNavigate
What Payers Evaluate
Comparative Effectiveness
Does this work better than what’s already being paid for? Placebo-controlled data satisfies the FDA, but rarely satisfies a payer.
Performance against the current standard of care is what matters.
Cost Justification
Is the clinical benefit meaningful enough to justify the cost?
Cost per outcome after factoring in any health service utilization cost offsets, such as hospital days. If you cannot frame this story in economic terms, payers will do it themselves, and the result is rarely favorable.
Real-World Applicability
Does the evidence apply to the patients who are actually covered?
Narrow enrollment and highly selected study populations raise questions about whether results translate to larger populations and real-world practice.
Budget Impact
What happens to the payer’s budget if this product is covered?
Even a clinically valuable product faces access barriers if the near-term financial impact appears too high.
1
The Evidence Snapshot™ – Payer Readiness Assessment for Biotech & MedTech
Entry Point · Low-Barrier Entry Consultation
An expert read on where your evidence stands — before the gaps cost you.
If you’ve never had a frank, expert conversation about your reimbursement readiness, this is where to start.
The Evidence Snapshot™ is our focused introductory 60-minutes consultation that gives your team:
- An honest assessment of where your evidence strategy stands today.
- Prioritizes key actions to take before payer-facing decisions begin.
Paired with our companion resource, What Payers Really Want e-book, teams leave with a clear framework through the lens of payers, health systems, and value committees regarding:
- Coverage
- Coding
- Payment
- Evidence generation
When The Evidence Snapshot™ Makes Sense
- You know reimbursement matters, but haven’t yet pressure-tested your strategy.
- Your team is preparing for investor conversations about reimbursement.
- Your team needs an expert preliminary read on evidence readiness.
- You want to test-drive our services before committing to a larger engagement.
What You Walk Away With
- Our proprietary primer: What Payers Really Want
- An honest, outside expert view of your current evidence strategy and reimbursement readiness.
- Identification of your single biggest reimbursement risk between now and launch.
- Prioritized next steps tailored to your product type, stage, and regulatory status.
- A clear, objective lens into what your payers, health systems, and value committees will require for reimbursement.
2
The Evidence Accelerator™ — Structured Payer-Readiness Audit
Payer-Readiness Audit
Many emerging companies wrongly assume that strong clinical evidence will translate to payer product coverage.
That’s not how it works.
Your endpoints may clear regulatory hurdles but miss what commercial and government payers actually require to say YES. By the time you find out, you are often looking at a 12- to 24-month setback.
Evidence Accelerator™ helps bring devices, diagnostics, digital therapeutics, and AI-enabled clinical tools to market.
- Reviews your evidence against payer requirements.
- Quantifies gaps and coverage risks.
- Produces three core outputs tied to a sequenced action plan.
When The Evidence Accelerator™ Makes Sense
- 12 to 18 months before launch.
- Investors are asking about reimbursement.
- You built strong scientific evidence, but your market access planning is lagging.
- You require a structured audit and a scored risk map.
- You need a sequenced action plan.
What You Walk Away With
A structured payer readiness audit delivers:
- Our Evidence Snapshot™: a clear picture of where your evidence stands for payer reimbursement.
- Risk Map: a scored assessment of what you may be missing by payer type.
- Action Roadmap: a sequenced plan with cross-functional team alignment and timelines.
- Board-ready confidence — present your reimbursement strategy to investors with data, not hope.
Three Phases of The Evidence Accelerator™
PhaSE 1: Evidence Review
Weeks 1-2
Phase 2: Gap Analysis
Weeks 3-4
PHASE 3: Action Plan
Weeks 5-6
Board-ready confidence: present your reimbursement strategy to investors with data, not hope.
3
The Evidence Architect: RWD™ — Full-Lifecycle Real-World Data Strategy
Full-Lifecycle Real-World Data Advisory
A data license is not a strategy.
Many real-world data (RWD) programs stall between data acquisition and business impact.
Analytics without strategic alignment leaves Medical Affairs, Value & Access, and Commercial working from different scripts.
Studies finish. Findings sit. ROI disappears.
Our Evidence Architect: RWD™ guides your RWD program through five structured phases, producing a coherent evidence narrative that serves:
- Medical Affairs
- Payer engagement
- Field use
- External launch messaging — not just internal decks.
When The Evidence Architect: RWD™ Makes Sense
- You have a real-world data (RWD) license, a planned RWD program, OR a study in progress.
- You need a cross-functional strategy and alignment around a coherent evidence narrative.
What You Walk Away With
- License ROI documented — a clear map from study outputs to business value, ready for leadership review
- Cross-functional alignment across Commercial, Medical Affairs, and Value & Access from day one
- Findings formatted for payers, KOLs, and field teams — not just internal decks
- Payer-facing evidence narrative with supporting data summaries
- KOL engagement toolkit derived from study findings
- Field team talking points grounded in real-world data
- Publication and congress abstract roadmap
- ROI summary linking data investment to commercial impact
5 Structured Phases of The Evidence Architect: RWD™
Discovery & Strategic Landscape
Study Intent & Strategic Framing
Protocol DevelopMENT & Support
Result Interpretation
External-Facing Strategy
4
The Evidence Communicator™ — Payer & Stakeholder Evidence Narratives
Translate Findings Into Deployment Narratives
Your study may be complete. The results may be real.
But results that stay in a data table do not change payer decisions, KOL conversations, or field team confidence.
Statistical outputs and clinical summaries do not speak the language of formulary decision makers.
Academic-style write-ups are not built for advisory boards or Congressional presentations.
MSLs tend to default to general messaging when evidence is not translated into their language.
Evidence Communicator™ closes that gap by transforming study findings into plain-language, audience-ready materials. Every asset is stress-tested for scientific accuracy and payer-appropriateness before it leaves the building.
When The Evidence Communicator™ Makes Sense
- You have completed study data (from any source — internal, CRO, academic literature, or MedNavigate).
- You need outputs designed for payers, KOLs, field teams, advisory boards, or Congress.
- You may or may not have previously engaged MedNavigate.
What You Walk Away With
- Audience-specific deployment narratives for payers, KOLs, field teams, and advisory boards.
- A scientifically accurate, payer-appropriate Evidence Brief ready for external use.
- Messaging frameworks tailored to each stakeholder audience.
- Stress-tested materials verified for scientific accuracy and payer-appropriateness.
- Field team and MSL talking points grounded in your study findings.
- Congress abstract and publication-ready language where applicable.
3 Phases of The Evidence communicator™
Framing & Foundation
We establish the full strategic foundation.
- Stakeholder interviews
- Scan of published evidence landscape
- Payer standards review
- Audience mapping
Asset Development
With the Phase 1, Evidence Framing Report, as the governing document, we build the external-facing asset(s).
Stress Test & Delivery
In phase 3, we:
- Verify every claim for scientific accuracy and payer-appropriateness.
- Simulate objections from payers, KOLs, and field audiences.
- Final package delivered with audience-specific usage guidance to then release materials externally.